Targeting HERI/EGFR: A molecular approach to cancer therapy

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J]. CANCER CELL, 2002, 2 (02) : 127 - 137

[2] Akita Robert W., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1003

[3] ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) : 774 - 782

[4] [Anonymous], P AM SOC CLIN ONCOL

[5] Arteaga CL, 2002, ONCOLOGIST, V7, P31

[6] Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[7] ZD1839 ('Iressa')1,2 as an anticancer agent [J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40

[8] HER-targeted tyrosine-kinase inhibitors [J]. ONCOLOGY, 2002, 63 : 6 - 16

[9] Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J]. ONCOLOGY, 2001, 61 : 14 - 21

[10] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J]. CANCER CELL, 2002, 2 (02) : 127 - 137

[2] Akita Robert W., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1003

[3] ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) : 774 - 782

[4] [Anonymous], P AM SOC CLIN ONCOL

[5] Arteaga CL, 2002, ONCOLOGIST, V7, P31

[6] Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[7] ZD1839 ('Iressa')1,2 as an anticancer agent [J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40

[8] HER-targeted tyrosine-kinase inhibitors [J]. ONCOLOGY, 2002, 63 : 6 - 16

[9] Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J]. ONCOLOGY, 2001, 61 : 14 - 21

[10] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302